Abstract
Invasive mycoses becoming more and more important problem of the modern medicine that is reflecting the increasing number of immunocompromised patients population. Despite the fact that the main causative agents remain Candida albicans, Aspergillus fumigatus and Cryptococcus neoformans, the number of cases of systemic fungal infection due to rare molds and nonalbicans strains of Candida spp. is increasing. Changes in the spectrum of causative agents and unacceptable high number of adverse events during the therapy with many of the traditional systemic antifungals leads to the necessity of creating new antifungal agents by widening of existing classes and by making new ones. In this article an attempt to describe the main representatives of the new antifungals and comparative analysis including pharmacokinetic, spectrum of activity, adverse events and the perspectives of their usage is made.
-
1.
Groll A.H., Shah P.M., Mentzel C., et al. Trends in postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33:23-32.
-
2.
Singh N. Trends in epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001; 33:1692-6.
-
3.
Liebowitz L.D., Ashbee H.R., Evans E.G.V., et al. A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Diagn Microbiol Infect Dis 2001; 4:27-33.
-
4.
Denning D.W. Therapeutic outcome of invasive aspergillosis. Clin Infect Dis 1996; 23:608-15.
-
5.
Kontoyiannis D.P., Mantadakis E., Samonis G. Systemic mycoses in the immunocompromised host: an update in antifungal therapy. J Hosp Infect 2003; 53:243-58.
-
6.
Wills E.A., Redinbo M.R., Perfect J.R., Del Poeta M. New potential targets for antifungal development. Emerg Ther Targets 2000; 4:1-32.
-
7.
Johnston D., Zhon X., Fukuoka T., et al. Voriconazole is highly active against the 14α-demethylase of Candida krusei. Proceedings of the 39th ICAAC, San Francisco, September 18, 1995. Abstract 125.
-
8.
Klepser M.E., Malone D., Lewis R.E., et al. Evaluation of voriconazole pharmacodynamics using time–kill methodology. Antimicrob Agents Chemother 2000; 44:1917-20.
-
9.
Pearson M.M., Rogers D., Cleary J.D., Chapman S.W. Voriconazole: a new triazole antifungal agent. Ann Pharmacother 2003; 37:420-32.
-
10.
Johnson E.M., Szekely A., Warnock D.W. In vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998; 42:741-5.
-
11.
Johnston D., Cannom R.R.M., Filler S.G. Amino acid substitutions in the Aspergillus fumigatus ERG11 gene product render it resistant to itraconazole yet susceptibility to voriconazole is maintained. Proceedings of the 40th ICAAC, Toronto; September 19, 2000. Abstract 1953.
-
12.
Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dermatiaceous fungi. J Clin Microbiol 2001; 39:954-8.
-
13.
Patterson B.E., Coates P.E. UK-109-496, a novel, widespectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man. Proceedings of the 35th ICAAC, San Francisco; September 18, 1995. Abstract F78.
-
14.
Greer N.D. Voriconazole: the newest triazole antifungal agent. BUMC Proceedings 2003; 16:241-8.
-
15.
Ghahramani P., Wood N.D., Kleinermans D., Love E.R. No significant pharmacokinetic interactions between voriconazole and indinavir. Proceedings of the 40th ICAAC, Toronto; September 18, 2000. p. 24.
-
16.
Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
-
17.
Ally R., Schurmann D., Kreisel W., et al. A randomized double-blind double-dummy multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33:1447-54.
-
18.
Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with Liposomal Amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:225-34.
-
19.
Torre-Cisneros J., Gonsales-Ruiz A., Hodges M.R., Lutsar I. Voriconazole for the treatment of S. apiospermum and S. prolificans infection. Proceedings of the Annual Meeting of the Infectious Diseases Society of America (New Orleans); 2000. Abstract 305.
-
20.
Perfect J.R., Lutsar I., Gonsales-Ruiz A. Voriconazole for the treatment of resistant and rare fungal infection. Proceedings of the 38th Annual Meeting of the Infectious Diseases Society of America (New Orleans); 2000. Abstract 303.
-
21.
Perfect J.R., Marr K.A., Walsh T.J., et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122-31.
-
22.
Walsh T.J., Lutsar I., Driscoll T., et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21:240-8.
-
23.
Johnson L.B., Kauffman C.A. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36:630-7.
-
24.
Fung-Tomc J.C., Huczko E., Minassian B., Bonner D.P. In vitro activity of a new oral triazole, BMS-207147 (ER30346). Antimicrob Agents Chemother 1998; 42:313-8.
-
25.
Carrillo A.J., Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001; 45:2151-3.
-
26.
Roberts J., Schock K., Marino S., Andriole V.T. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000; 44:3381-8.
-
27.
Yamazumi T., Pfaller M.A., Messer S.A., et al. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 2000; 44:2883-6.
-
28.
Pfaller M.A., Messer S.A., Hollis R.J., et al. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002; 46:1723-7.
-
29.
Kirkpatrick W.R., Perea S., Coco B.J., Patterson T.F. Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. J Antimicrob Chemother 2003; 49:353-7.
-
30.
Groll A.H., Piscitelli S.C., Walsh T.J. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998; 44:343-50.
-
31.
Petraitiene R., Petraitis V., Groll A.H., et al. Antifungal activity and pharmacokinetics of posaconazole (SCH56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001; 45:857-69.
-
32.
Manavathu E.K., Cutright J.L., Loebenberg D., Chandrasekar P.H. A comparative study of the in vitro susceptibilities of clinical and laboratory selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 2000; 46:229-34.
-
33.
Cacciapuoti A., Loebenberg D., Corcoran E., et al. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother 2000; 44:2017-22.
-
34.
Marco F., Pfaller M.A., Messer S.A., Jones R.N. In vitro activity of a new triazole antifungal agent SCH56592, against clinical isolates of filamentous fungi. Mycopathol 1998; 141:73-7.
-
35.
Connolly P., Wheat L.J., Schnizlein-Bick C., et al. Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. Antimicrob Agents Chemother 2000; 44:2604-8.
-
36.
Barchiesi F., Schimizzi A.M., Najvar L.K., et al. Interactions of posaconazole and flucytosine against Cryptococcus neoformans. Antimicrob Agents Chemother 2001; 45:135-9.
-
37.
Tobon A.M., Arango M., Fernandez D., Restrepo A. Mucormycosis (Zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis 2003; 36:1488-91.
-
38.
Mellinghoff I.K., Winston D.J., Mukwaya G., Schiller G.J. Treatment of S. apiospermum brain abscesses with posaconazole. Clin Infect Dis 2002; 34:1648-50.
-
39.
Hachem R.Y., Raad I., Afif C.M., et al. An open, noncomparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections (IFI) refractory to or intolerant (I) to standard therapy (ST). Proceedings of the 40th ICAAC; Toronto, Canada; 2000. Abstract 112.
-
40.
Capilla J., Yustes C., Mayayo E., et al. Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbit. Antimicrob Agents Chemother 2003; 47:1948-51.
-
41.
Denning D.W. Echinocandins: a new class of antifungal. J Antimicrob Chemother 2002; 49:889-91.
-
42.
Letscher-Bru V., Herbrecht R. Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 2003; 51:513-21.
-
43.
Vazquez J.A., Lynch M., Boikov D., Sobel J.D. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997; 41:1612–4.
-
44.
Krishnarao T.V., Galgiani, J.N. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother 1997; 41:1957–60.
-
45.
Feldmesser M., Kress Y., Mednick A., Casadevall A. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J Infect Dis 2000; 182:1791–5.
-
46.
Arikan S., Lozano-Chiu M., Paetznick V., Rex J.H. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2001; 45:327–30.
-
47.
Pfaller M.A., Marco F., Messer S.A., Jones R.N. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998; 30:251-5.
-
48.
Del Poeta M., Schell W.A., Perfect J.R. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother 1997; 41:1835–6.
-
49.
Arikan S., Lozano-Chiu M., Paetznick V., Rex J.H. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46:245–7.
-
50.
Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36:2950–6.
-
51.
Kohler S., Wheat L.J., Connolly P., et al. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob Agents Chemother 2000; 44:1850–4.
-
52.
Matsumoto Y., Matsuda S. Tegoshi T. Yeast glucan in the cyst wall of Pneumocystis carinii. J Protozoology 1989; 36:21S–22S.
-
53.
Villanueva A., Arathoon E.G., Gotuzzo E., et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33:1529-35.
-
54.
Arathoon E.G., Gotuzzo E., Noriega L.M., et al. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2002; 46:451-7.
-
55.
Villanueva A., Gotuzzo E., Arathoon E.G., et al. A randomized, double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113:294-9.
-
56.
Mora-Duarte J., Betts R., Rotstein C., et al. Caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neutropenic and non neutropenic patients: a multicentre randomized double-blind study. Clin Microbiol Infect 2002; 8:33-4.
-
57.
Maertens J., Raad I., Petrikos G., et al. Update of the multicenter, noncomparative study of caspofungin in adults with invasive aspergillosis refractory or intolerant to other antifungal agents: an analysis of 90 patients. Proceedings of the 42nd ICAAC, San Diego, USA; 2002. p. 388.
-
58.
Kantoyiannis D.P., Hachem R., Lewis R.E., et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematological malignancies. Cancer 2003; 98:292-9.
-
59.
Aliff T.B., Maslak P.G., Jurcic J.G., et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin B. Cancer 2003; 97:1025-32.
-
60.
Uchida K., Nishiyama Y., Yokota N., Yamaguchi H. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J Antibiot 2000; 53:1175-81.
-
61.
Mikamo H., Sato Y., Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandinlike lipopeptide. J Antimicrob Chemother 2000; 46:485-7.
-
62.
Ullmann A.J., Van Burik J.A., McSweeney P., et al. An open phase II study of the efficacy of micafungin (FK463) alone and in combination for the treatment of invasive aspergillosis in adults and children. Proceedings of the 13th ECCMID; Glasgow, UK; May 10-13, 2003. Abstract O400.
-
63.
Van Burik J., Ratanatharathorn V., Lipton J., et al. Randomized, double-blind trial of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hemopoietic stem cell transplant. Proceedings of the 42nd ICAAC; San Diego, USA; 2002. p. 401.
-
64.
Arevalo M.P., Carrillo-Munoz A.J., Salgado J., et al. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J Antimicrob Chemother 2003; 51:163-6.
-
65.
Serrano M.C., Valverde-Conde A., Chavez M.M., et al. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY-303366) and amphotericin B against Aspergillus spp. Diagn Microbiol Infect Dis 2003; 45:131-5.
-
66.
Moore C.B., Oakley K.L., Denning D.W. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin Microbiol Infect 2001; 7:11-6.
-
67.
Cuenca-Estrella M., Mellado E., Diaz-Guerra T.M., et al. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. J Antimicrob Chemother 2000; 46:475-7.
-
68.
Dowell J., Stogniew M., Krause D. Anidulafungin dosage adjustments are not required for patients with hepatic and/or renal impairment. Proceedings of the 13th ECCMID; Glasgow, UK; May 10-13, 2003. Abstract P1222.
-
69.
Pace H.R., Schantz S.I. Nystatin (Mycostatin) in the treatment of monilial and nonmonilial vaginitis. J Am Med Assoc 1956; 162:268-71.
-
70.
Stark J.E. Allergic pulmonary aspergillosis successfully treated with inhalations of nystatin. Dis Chest 1967; 51:96-9.
-
71.
Ng A.W., Wasan K.M., Lopez-Berestein G. Development of liposomal polyene antibiotics: an historical perspective. J Pharm Pharmaceut Sci 2003; 6:67-83.
-
72.
Wallace T.L., Paetznick B., Cossum P.A., et al. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob Agents Chemother 1997; 41:2238-43.
-
73.
Groll A.H., Gonzales C.E., Giri N., et al. Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and noncompartmental pharmacokinetics. J Antimicrob Chemother 1999; 43:95-103.
-
74.
Rios A., Rosenblum M., Crofoot G., et al. Pharmacokinetics of liposomal nystatin in patients with human immunodeficiency virus infection. J Infect Dis 1993; 168:253-4.
-
75.
Krupova Y., Mistrik M., Bojtarova E., et al. Liposomal nystatin (L-NYS) in therapy of pulmonary aspergillosis refractory to conventional amphotericin B in cancer patient. Support Care Cancer 2002; 9:209-10.
-
76.
Gunawardana G., Rasmussen R.R., Scherr M., et al. Corynecandin: a novel antifungal glycolipid from Coryneum modonium. J Antibiot 1997; 50:884-6.
-
77.
Jackson M., Frost D.J., Karwowski J.P., et al. Fusacandins A and B: Novel antifungal antibiotics of the papulacandin class from Fusarium sambucinum. I. Identity of the producing organism, fermentation and biological activity. J Antibiot 1995; 48:608-13.
-
78.
Dominguez J.M., Kelly V.A., Kinsman O.S., et al. Sordarins: A new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts. Antimicrob Agents Chemother 1998; 42:2274-8.
-
79.
Dominguez J.M., Martin J.J. Identification of elongation factor 2 as the essential protein targeted by sordarins in Candida albicans. Antimicrob Agents Chemother 1998; 42:2279-83.
-
80.
Konishi M., Nishio M., Saitoh K., et al. Cispentacin, a new antifungal antibiotic. I. Production, isolation, physico-chemical properties and structure. J Antibiot 1989; 42:1749-55.
-
81.
Capobianco J.O., Zakula D., Coen M.L., Goldman R.C. Anti-Candida activity of cispentacin: The active transport by amino acid permeases and possible mechanisms of action. Biochem Biophys Res Commun 1993; 190:1037-44.
-
82.
Oki T., Hirano M., Tomatsu K., et al. Cispentacin, a new antifungal antibiotic. II. In vitro and in vivo antifungal activities. J Antibiot 1989; 42:1756-62.
-
83.
Fujiu M., Sawairi S., Shimaka H., et al. Azoxybacillin, a novel antifungal agent produced by Bacillus cereus NR2991. J Antibiot 1994; 47:833-5.
-
84.
Aoki Y., Kondah M., Nakamura M., et al. A new methionine antagonist which has antifungal activity: Mode of action. J Antibiot 1994; 47:909-15.